Sei sulla pagina 1di 26
RIQAS explained The largest global EQA scheme, serving over 20,000 laboratories InternatIonal QualIty assessment scheme
RIQAS explained The largest global EQA scheme, serving over 20,000 laboratories InternatIonal QualIty assessment scheme
RIQAS explained The largest global EQA scheme, serving over 20,000 laboratories InternatIonal QualIty assessment scheme

RIQAS explained

The largest global EQA scheme, serving over 20,000 laboratories

RIQAS explained The largest global EQA scheme, serving over 20,000 laboratories InternatIonal QualIty assessment scheme
RIQAS explained The largest global EQA scheme, serving over 20,000 laboratories InternatIonal QualIty assessment scheme
RIQAS explained The largest global EQA scheme, serving over 20,000 laboratories InternatIonal QualIty assessment scheme
RIQAS explained The largest global EQA scheme, serving over 20,000 laboratories InternatIonal QualIty assessment scheme

InternatIonal QualIty assessment scheme

EQA

External Quality Assessment (EQA) is an essential aspect of any laboratory operation. EQA provides a means of assessing the analytical performance of a laboratory compared to other laboratories utilising the same methods and instruments.

Overall objective of EQA

To develop inter-laboratory comparability which allows standardisation of diagnostic testing. EQA measures a laboratory's accuracy using 'blind' samples that are analysed as if they were patient samples. Results are returned to the scheme organiser for statistical analysis. Laboratories receive a report comparing their individual performance against other participants in the programme. EQA has a number of functions:

Maintaining and improving the analytical quality of laboratory tests

Improving inter-laboratory agreement and raising standards

Detecting equipment failures, identifying reagent problems, reviewing staff training

Initiating and evaluating corrective actions

Comparing different analytical methods

Participation in an EQA scheme will help produce reliable and accurate reporting of patient results. Quality results will reduce time and labour costs, and most importantly provide accurate patient diagnosis and treatment.

RIQAS Programmes

• Blood Gas

• Cardiac

• Clinical Chemistry

• Coagulation

• Glycated Haemoglobin (HbA1c)

• Human Urine

Haematology

rIQas support

(HbA1c) • • Human Urine Haematology rIQas support • Immunoassay • Immunoassay Speciality 1 • Immunoassay

• Immunoassay

• Immunoassay Speciality 1

• Immunoassay Speciality 2

• Lipid

• Liquid Cardiac

• Maternal Screening

• Specific Proteins

• Therapeutic Drugs

• Urinalysis

• Urine Toxicology

• Serology (HIV/ Hepatitis)

• Serology (ToRCH)

• Serology Epstein Barr Virus (EBV)

• Serology (Syphilis)

RIQAS support staff are on hand to offer advice and troubleshoot technical queries

EQA

RIQAS is the largest international EQA scheme in the world. It is used by more than 20,000 laboratories in 100 countries worldwide.Twenty one programme types are currently available.

one programme types are currently available. Accreditation RIQAS provides Certificates as proof of EQA

Accreditation

RIQAS provides Certificates as proof of EQA participation for laboratory accreditation purposes.

Randox and RIQAS systems and procedures are accredited to a number of internationally recognised standards:

ISO 13485:2003 for the design and manufacture of medical devices

Recognised by the UK National Quality Assurance Advisory Panel (NQAAP) for Clinical Pathology

Recognised by the Joint Working Group on Quality Assurance (JWG QA)

RIQAS is a UKAS accredited Proficiency Testing Provider, No. 0010, and is accredited to ISO/IEC 17043:2010, 'Conformity Assessment- General Requirements for Proficiency Testing', which cancels and replaces ISO/IEC Guide 43 - (1+2) and ILAC G13:2007.

These certifications highlight the superior quality and excellence of RIQAS

Independent Advisory Panel

RIQAS participants have access to an independent advisory panel consisting of scientific and clinical experts.This ensures professional and ethical conduct of the scheme and participant confidentiality.

RIQAS Facts

A good EQA scheme should have:

Sufficient number of participants

Effective consolidation of programmes

International recognition through accreditation

Quality material

Regular reports with rapid turnaround times

Independent advisory panel

Flexible programme choices

RIQAS Features and Benefits

RIQAS samples are custom-manufactured to be both stable and similar to human samples.

A high level of participation ensures a large database of results and analytical methods, therefore increasing statistical validity

Programmes accepted by National and International accreditation bodies worldwide

Human samples free from interfering preservatives increase confidence that EQA performance mirrors the performance of patient samples

Optimised shipping of samples for each cycle

Wide range of parameters covering a broad spectrum of laboratory testing

Regular reports with rapid turnaround, ensuring corrective actions can be taken prior to analysis of subsequent samples

User friendly reports, easy to read at a glance, saving valuable laboratory time

Reduced parameter options for selected programmes offer greater flexibilty, ensuring suitability for laboratories of all sizes and budgets

Participant certificates provide evidence of participation in a reputable EQA scheme

Multi-instrument reports allow assessment of performance of all systems in the laboratory

Inter-laboratory group reports allow comparison of multiple connected laboratories

Reference method values are provided in the Clinical Chemistry programme for 12 parameters

RIQAS Reports

RIQAS reports are presented in a user friendly, one page per parameter format.This allows easy interpretation of your analytical performance.

RIQAS Reports

Statistical breakdown by all methods, your method and, where applicable, your instrument including running means for the last 10 samples

Compare your instrument group, method group and all methods using the histogram

Identify trends, biases and precision problems using the visual charts

The Target Score chart grades your performance in a moving window over the last 20 samples, including the previous cycle

At-a-glance summary page for all parameters in the programme

Compare your result with statistically robust consensus means

Identify acceptable and poor performance using fit-for-purpose performance indicators:

- SD1

- % Deviation

- Target Score

Multi-Instrument Reports

Laboratories can register up to five instruments at no extra cost. Individual reports for each instrument plus a unique multi-instrument report are provided.

The multi-instrument report allows the comparative performance of each instrument. Additional sample packs may be ordered as required.

Additional sample packs may be ordered as required. PDF Reporting RIQAS reports can now be presented

PDF Reporting

RIQAS reports can now be presented in pdf (portable document format), offering easy review and storage of your laboratory’s EQA data.

There are many advantages associated with pdf reporting, increasing the usability and efficiency of data analysis.

Summary CSV files

It is possible to receive an additional summary of your report statistics and performance indicators as a .csv file for every sample.

RIQAS Facts

Inter-laboratory group reports:

The Group Reporting facility enables laboratory groups to monitor satellite sites. Laboratories can receive individual reports with the group supervisor receiving a report comparing the laboratories within the group. This allows easy assessment of performance of all laboratories within a group.

Web-Based Data Transfer

The rIQasNet system offers easy direct access for the submission of results and retrieval of reports straight from the rIQas host server.

retrieval of reports straight from the rIQas host server. • Website available in multiple languages •
retrieval of reports straight from the rIQas host server. • Website available in multiple languages •
retrieval of reports straight from the rIQas host server. • Website available in multiple languages •

Website available in multiple languages

Confidentiality and security is maintained through the use of password protected access

Submit current, corrected, late and future results (normal policies apply), directly into RIQAS database. Receipt of results is confirmed by e-mail.

Additions and changes to assay details can be made online.

Reports are emailed in pdf format as soon as they are prepared

Up to two cycles of reports are available to be downloaded from website

View, print, store or distribute reports as you wish

All that is required is web access, Adobe Reader (for viewing reports) and a valid password to access system. No additional software required.

web access, Adobe Reader (for viewing reports) and a valid password to access system. No additional

Standard Report

Performance data is presented in a one page format with up to seven sub-reports

1 4 N C 5 6 2 3 7
1
4
N C
5
6
2
3
7
1
1

Text Section:

Statistics for all methods, your method and instrument group (Programme specific)

2
2

Histogram:

Method and instrument comparison

3
3

Multi Method Stat Section:

Enables assessment of the performance of each method

4
4

Levey-Jennings Chart:

Details features of your laboratory’s performance

5
5

Target Score:

This unique chart provides a numerical index of performance, allowing at a glance assessment

6
6

% Deviation by Sample:

Helps to identify trends and shifts in performance

Text Section

2 3 4 5 6 7 1 9 10 11 10 8 12 10 13
2
3
4
5
6
7
1
9
10
11
10
8
12
10
13
14
Performance statement appears here if performance indicators exceed limits

RIQAS performance indicators include SDI, Target score and % deviation.

Acceptable performance criteria:

SDI <2SDPA Target score >50 % deviation < defined acceptable limits

1
1

Report is presented in your chosen unit

2
2

Number of returned results used to generate mean for comparison

3
3

Average value of all laboratories’ results

4
4

Coefficient of Variation

5
5

Uncertainty associated with the mean for comparison

u m =

1.25 x SD n

6
6

SDPA = Standard Deviation for Performance Assessment, calculated from the Target Deviation for Performance Assessment (TDPA) and the mean for comparison.

SDPA = TDPA x Mean for comparison t-value x 100

t-value

reflected in the TDPA (t-value ~ 1.645 when ~10% laboratories achieve poor performance) SDPA is combined with Um, where appropriate.

=

factor which represents the % of poor performers

If U m > ( 0.3 x SDPA) then SDPA adjusted = ( U m 2 + SDPA 2 ) and

the reported value is suffixed with "a"

If U m is less than ( 0.3 x SDPA) then SDPA adjusted

= SDPA

After statistical reduction, some results are excluded

Ideally this will be your instrument group mean. If N<5 for instrument group, your method group mean is selected as Mean for comparison

Standard Deviation Index = Your result - Mean for comparison

SDPA adjusted

Running Mean average of the last 10 performance indicators is used to monitor performance over time and concentration range

Target Score - The closer a value is to 120, the better the performance

% Deviation from the mean for comparison - the closer the value is to zero, the better the performance

Biological variation stated for information purposes only

Performance limit set for this parameter

Histogram

The Bar Graph is intended as a quick visualisation of how your lab’s result falls into the overall picture of:

Your instrument group (programme specific)

All methods Your method group 1 2 5 4 3 1 Total of 298 laboratories
All methods
Your method group
1
2
5
4
3
1
Total of 298 laboratories reported values between 109.35 and 111.20
RIQAS reports show your unit of measurement
2
31 laboratories reported values between 103.05 and 104.41 in your
method group
13 laboratories reported values between 111.20 and 112.56 in your
instrument group
3
Your Result

Levey Jennings Chart

SDIs reflect laboratory performance in relation to fit-for-purpose SDPAs and are useful to monitor performance over time. Acceptable performance is SDI < 2SDPA.

1 2 3 N L C 4 5 6 7
1
2
3
N
L
C
4
5
6
7
1
1

The mean for comparison for each sample is indicated at the top of

4
4

N = No result returned from your laboratory

the chart, allowing easy assessment of concentration related bias:

 
5
5
 

I:

Instrument mean Method mean All method mean

Sample number

M:

 

A:

6
6

L = Late result received after “final date” deadline. Late results will be accepted up until the “final date” of the next sample

2
2

This line indicates a change in registration details for this parameter

 
7
7

C = Corrected results will be accepted in exceptional cases where, for example, you have made a transcription error. Corrected results will be accepted up to 4 weeks after the final date deadline

3
3

Your SDI (Standard Deviation Index)

Target Score Chart

The Target Score (TS) allows participants to assess their performance at a glance. The TS relates the % deviation of your result from the mean to a Target Deviation for Performance Assessment (TDPA). TDPAs are set to encourage participants to achieve and maintain acceptable performance. TDPAs are fit-for-purpose performance criteria which are set taking guidance from ISO/IEC17043, ISO13528 and IUPAC. Target Deviations for Performance Assessment are also used to calculate the Standard Deviation for Performance Assessment (SDPA).

1 2 3 N L C
1
2
3
N
L
C

Excellent

Good

Acceptable

Need for improvement

Unacceptable

1
1

This is the upper deviation limit of performance for this parameter. TDPAs are reviewed regularly and deemed fit for purpose by the RIQAS Advisory Panel.

High score >50 in the lighter shaded area represents acceptable, good or excellent performanceand deemed fit for purpose by the RIQAS Advisory Panel. Heavy shading for values 10 to

Heavy shading for values 10 to 50 signifies poor performanceAdvisory Panel. High score >50 in the lighter shaded area represents acceptable, good or excellent performance

% Deviation by Sample Chart

This chart helps to identify trends and shifts in performance.

% Deviation = Your result - Consensus mean

Consensus mean

x 100%

1 2 3 N C
1
2
3
N
C
1
1

%

Deviation from mean for comparison

3
3

Acceptable limits of performance.These are defaulted to RIQAS TDPAs but can be set to e.g. biological variation or regulatory requirement on request.

2
2

Plot of running mean % deviations (average of the last 10

% deviations for the sample indicated)

% Deviation by Concentration Chart

This chart enables rapid assessment of concentration related biases. Biases at low or high concentrations may be easily determined, also whether a particular sample is a random outlier or if a bias is always present at that concentration.

2 1
2
1
1
1

Current sample indicated by square

2
2

% Deviation at specific concentration

Multi Method Stat Section

This section provides an easy way of assessing the performance of the other methods used to analyse the parameter.

Method

n

Mean

CV%

u m

Hexokinase

978

109.285

2.4

0.10

Glucose oxidase Ortho Vitros MicroSlide Systems GOD/02-Beckman method Oxygen electrode Glucose dehydrogenase

476

112.977

3.8

0.25

115

105.688

2.3

0.28

44

108.155

2.4

0.50

23

107.764

3.2

0.90

12

109.292

3.2

1.27

Summary Page

1 xxxxx 2 4 5 12.7 3 6 7 8
1
xxxxx
2
4
5
12.7
3
6
7
8
1
1

Your unique and confidential laboratory identification

4
4

RM % DEV - Average of the last 10 %DEV for this parameter

2
2

RMSDI - is the Running Mean of the 10 previous SDIs (if fewer than 10 results on file,“Too Few” is printed)

5
5

RMTS - Average of the last 10 Target Scores for this parameter

6
6

Overall RMSDI = average RMSDI for this sample distribution

3
3

Red triangle appears when all performance indicators (SDI, %DEV and TS) exceed acceptable performance, i.e: when SDI > 2SDPA TS < 50 %DEV > acceptable limits set

7
7

Overall RM%DEV = average RM%DEV for this sample distribution

8
8

Overall RMTS = average RMTS for this sample distribution

Urine Toxicology Report

SCREENING SECTION

QUANTITATIVE SECTION

Urine Toxicology Report SCREENING SECTION QUANTITATIVE SECTION 16

Screening Section

4 5 6 7 8 9
4
5
6
7
8
9
1 2 3
1
2
3
10
10

Performance History

Performance History 11 12 13 14 15
Performance History 11 12 13 14 15
11 12 13 14 15
11
12
13
14
15
1
1

Screening Text Section

6
6

Screening results for all cut-offs returned for this sample within your method group.

2
2

Screening Results: This chart is a quick visualisation of your performance over the last 20 samples.A result in the white section indicates a correct response. A result in the upper red section indicates a False Positive response, and a result in the lower red section indicates a False Negative response.

7
7

Total screening results over all your cut-offs for your laboratory’s method.

8
8

Screening results for all cut-offs returned for this sample over all methods

 
9
9

Total screening results over all cut-offs for all methods.

3
3

Comment section for RIQAS to provide your laboratory with additional relevant information regarding this sample, such as spiked metabolite concentration

10
10

Screening results for other methods using same cut-off as the laboratory.

 
11
11

Performance history for this parameter, based on previous 10 samples.

4
4

Screening result response categories. All abbreviations indicated at the bottom of the report page. Key

12
12

Performance of your method over all cut-offs for this sample

TN - true negative FP - false positive

TP - true positive

FN - false negative

13
13

Performance history of your method over all cut-offs, based on the previous 10 samples

RC - sent for confirmation

NT - not tested

5
5

Screening Summary:Your screening result shown in the appropriate response category and your cut off for this sample.

14
14

Performance of all methods over all cut-offs for this sample

 
15
15

Performance history of all methods over all cut-offs, based on the previous 10 samples

Quantitative Section

1
1
 

 

          4     5  

          4     5  

 

      4

      4

   
4
4

 

 

5  

5  

5
5
 

    4     5   1 Quantitative Text Section: Comparison statistics. Caution

    4     5   1 Quantitative Text Section: Comparison statistics. Caution

1 Quantitative Text Section: Comparison statistics. Caution is needed when the N value is too
1
Quantitative Text Section: Comparison statistics. Caution is needed
when the N value is too small to support statistical significance
2
Your Result
3
Your Mean for Comparison
4
Standard Deviation Index = (Your Result – Mean for Comparison)
SD of Mean for comparison
 

5
5

Running mean SDI = average of last 10 SDIs for this parameter (If fewer than 10 results, "Too Few" is printed)

6
6

Quantitative Results Histogram:This graph provides a quick visualisation of how your quantitative result falls into the overall picture for all methods and your method group

7
7

All available method statistics for this sample

18

Urinalysis Report

SCREENING RESULTS

1 2 11 12 3 4 5 6 13 7 14 15 8 16 10
1
2
11
12
3
4
5 6
13
7
14
15
8
16
10
10
9
17
1
1

Categories are stated in your unit

10
10

Your Result

2
2

Your method group and categories

11
11

All categories (result options) available for this parameter for any method (dipstick)

3
3

Results from all methods (dipsticks) returning results in the same categories as your lab

12
12

Your categories (available result options for chosen dipstick and unit)

4
4

Results from all methods for all available categories

13
13

Comments Box

5
5

Your Result

14
14

All Categories Histogram: a quick visualisation of how your lab’s result falls into the overall picture for all categories

6
6

Performance Statement

 
15
15

Results submitted from a category not applicable to your method

7
7

Your Categories Histogram:A quick visualisation of how your lab’s result falls into the overall picture for your categories

16
16

Your categories

8
8

Possible reporting categories for your method

17
17

Detailed summary of results:This table enables you to see how you compare to all other results

9
9

All available methods for this parameter

Serology: Screening (Qualitative) Report

Your performance for multiple samples is presented in a convenient single report per quarterly distribution

HBsAg

Sample 2

Your Result:

Positive

Your

method:

Abbott Architect

Most common result:

Positive

Overall results

Negative:

34

2
2

Equivocal:

9

Positive:

446

1
1

Method

N

Negative

Equivocal

Positive

Abbott Architect

124

1

0

123

Roche Cobas 6000/8000

46

0

2

44

Roche Cobas 4000/e411

46

2

1

43

Siemens/Bayer ADVIA Centaur

44

0

1

43

Abbott Axsym

41

2

0

39

Roche Elecsys

33

1

0

32

4
4

Biomerieux VIDAS

25

0

0

25

Roche Modular E170

20

0

1

19

Ortho Vitros 3600/5600/ECi

19

0

1

18

Bio-Rad HBs PLUS

11

0

0

11

Beckman Access/LXi725

10

0

0

10

Siemens/DPC Immulite 2000/2500

9

1

1

7

Beckman DxI 600/800

7

0

0

7

SD Bioline Rapid Test HBsAg

7

5

1

1

400 350 300 250 200 150 100 50 0 Number of Laboratories
400
350
300
250
200
150
100
50
0
Number of Laboratories

Negative

Equivocal

Positive

3
3

Your qualitative result and chosen method are presented along with the most common result category50 0 Number of Laboratories Negative Equivocal Positive 3 Overall Summary shows the number of results

Overall Summary shows the number of results for this parameter and sample which are negative, equivocal or positiveare presented along with the most common result category Your result is shown as a black

Your result is shown as a black triangle on the category chart compared to other laboratories in groups:and sample which are negative, equivocal or positive All Methods Your Method Summary shows performance of

All Methods

chart compared to other laboratories in groups: All Methods Your Method Summary shows performance of all

Your Method

to other laboratories in groups: All Methods Your Method Summary shows performance of all the methods

Summary shows performance of all the methods used to analyse the parameteris shown as a black triangle on the category chart compared to other laboratories in groups:

Serology: Screening (Quantitative) Report

Your performance for multiple samples is presented in a convenient single report per quarterly distribution

Anti-Rubella IgG, IU/ml

report per quarterly distribution Anti-Rubella IgG, IU/ml Sample 2   N Mean CV% All methods 210

Sample 2

 

N

Mean

CV%

All methods

210

92.574

37.2

Abbott Architect

39

83.219

8.7

U m

2.97

1.46

SDPA

34.42

7.27

Exc.

31

5

1
1
Your Result 84.800 SDI 0.22 RMSDI Too Few Mean for Comparison 83.219 3
Your Result
84.800
SDI
0.22
RMSDI
Too Few
Mean for Comparison
83.219
3

Method

N

Mean

CV%

Biomerieux VIDAS

48

150.979

9.8

Abbott Architect

44

83.219

8.7

Roche Cobas 6000/8000

18

58.792

3.6

Abbott Axsym

17

108.206

18.0

Siemens/DPC Immulite 2000/2500

17

90.800

6.2

Roche Cobas 4000/e411

17

59.973

7.0

Siemens/Bayer ADVIA Centaur

14

120.775

11.0

Roche Elecsys

11

57.043

3.9

Diasorin Liaison

9

52.388

18.0

Roche Modular E170

9

58.949

3.9

Beckman DxI 600/800

6

125.817

7.4

U m

2.97

1.46

0.68

6.09

1.94

1.35

5.88

1.05

4.16

1.08

4.75

60 50 40 30 20 10 0 < 24.47 73.43 122.39 171.35 > IU/ml 2
60
50
40
30
20
10
0
<
24.47
73.43
122.39
171.35
>
IU/ml
2
Number of Laboratories
1
1

Quantitative statistics for “All Methods” and “Your Method” are presented in your chosen unit along with your result and your performance scores (SDI and RMSDI).

3
3

Multi Method Statistics section provides an easy way of assessing the performance of the methods used to analyse the parameter

2
2

Your result is presented on the bar graph as a black triangle, showing how you compare to the :

All Methods

Your result is presented on the bar graph as a black triangle, showing how you compare

Your Method

Your result is presented on the bar graph as a black triangle, showing how you compare

RIQAS Programmes

BLOOD GAS PROGRAMME With target scoring

RQ9134

RQ9134/A

First registered instument

Subsequent instruments

10

Parameters

10 Parameters

Samples every month, 1 x 12 month cycle, 12 month subscription

 

pCO2

tCO2

K+

Lactate

pH

Ca++

Na+

 

pO2

Cl-

Glucose

CARDIAC PROGRAMME With target scoring

 

RQ9127/a

RQ9127/b

2

Parameters only (choose from 7)

Full 7 Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

 

CK,Total CK-MB Activity units

CK-MB Mass units Homocysteine

Myoglobin

Troponin T

Troponin I

COAGULATION PROGRAMME With target scoring

RQ9135/a

RQ9135/b

5 selected Parameters only

Full 16 parameters

(aPTT, PT,TT, Fibrinogen, Antithrombin III) Samples every month, 1 x 12 month cycle, 12 month subscription

 

aPTT PT (including INR) TT Fibrinogen

Antithrombin III

Factor II

Factor IX

Plasminogen

Factor V

Factor X

Protein C

Factor VII

Factor XI

Protein S

Factor VIII

Factor XII

GENERAL CLINICAL CHEMISTRY PROGRAMMES With target scoring

 

RQ9112

RQ9112/S

RQ9113

10 Parameters only

17 Parameters only

Full 50 Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription, Reference Method Values

Acid phosphatase, prostatic Acid phosphatase, total Albumin Alkaline phosphatase ALT (ALAT) Amylase, pancreatic Amylase, total AST (ASAT) Bicarbonate Bile acids Bilirubin, direct Bilirubin, total Calcium

Calcium, ionised Chloride Cholesterol Cholinesterase* CK, total (CPK) Copper Creatinine

HDL-Cholesterol

Sodium

Iron

TIBC

Lactate*

Free T3

LD (LDH)

Total T3

Lipase

Free T4

Lithium

Total T4

Magnesium

Triglycerides

D-3-hydroxybutyrate

NEFA*

TSH

Fructosamine*

Osmolality

Urea

Gamma GT

Phosphate, inorganic

Uric acid

GLDH

Potassium

Zinc

Glucose

Protein, total

HBDH

PSA

GLYCATED HAEMOGLOBIN PROGRAMME (HbAlc) With target scoring

RQ9129

 

2

Parameters

Samples every month, 1 x 12 month cycle, 12 month subscription

 

HbA1c

Total Haemoglobin

HAEMATOLOGY PROGRAMME With target scoring

 

RQ9118

 

12

Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

 

Haematocrit (HCT) Haemoglobin (Hb) Mean Cell Haemoglobin (MCH) Mean Cell Haemoglobin Concentration (MCHC) Mean Cell Volume (MCV) Mean Platelet Volume* (MPV)

 

Packed Cell Volume* (PCV) Platelets (PLT) Plateletcrit* (PCT) Red Blood Cell Count (RBC) Red Cell Distribution Width* (RDW) Total White Blood Cell Count (WBC)

HUMAN URINE PROGRAMME With target scoring

RQ9115

 

24 Parameters Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

 

Albumin/Microalbumin

Creatinine

Normetanephrine

Protein, total

Amylase

Dopamine

Magnesium

Sodium

Calcium

Epinephrine

Osmolality

Urea

Chloride

Glucose

Oxalate

Uric acid

Copper

Metanephrine

Phosphate, inorganic

VMA

Cortisol

Norepinephrine

Potassium

5-HIAA

RED = Parameters with Reference Method Values

PURPLE = The only parameters available on RQ9135/a

+ = Programmes awaiting accreditation to ISO/IEC 17043

* = Pilot study ongoing

RIQAS Programmes

IMMUNOASSAY PROGRAMMES With target scoring

RQ9125/a

RQ9125/b

RQ9125/c

RQ9130

4 Parameters only (choose from 55)

13 Parameters only (choose from 55)

Full 55 Parameters

Full 55 Parameters

Samples every two weeks, 2 x 6 monthly cycles (RQ9125/a, RQ9125/b, RQ9125/c) , 12 month subscription Samples every month, 1 x 12 month cycle (RQ9130), 12 month subscription

ACTH*

DHEA Unconjugated

17-OH-progesterone

Free T4 Total T4 Testosterone, free Testosterone, total Theophylline Thyroglobulin Tobramycin* TSH Valproic acid Vancomycin* Vitamin B12 1-25-(OH) ² -Vitamin D* 25-OH-Vitamin D*

 

AFP

Digoxin

Paracetamol*

Aldosterone*

Estriol Total*

Phenobarbital*

Amikacin*

Ethosuximide*

Phenytoin

Androstenedione*

Ferritin

Primidone*

Beta-2-microglobulin

Folate

Progesterone

CA125

FSH

Prolactin

CA15-3

Gentamicin*

Free PSA

CA19-9

GH

Total PSA

Carbamazepine

hCG

PTH

 

CEA

IgE

Salicylate*

Cortisol

Insulin

SHBG

C-peptide*

LH

Free T3

DHEA-S

Oestradiol

Total T3

IMMUNOASSAY SPECIALITY 1 PROGRAMME+

RQ9141

 

10 parameters Samples every month, 1 x 12 month cycle, 12 month subscription

 
 

Anti-TPO

PTH

1-25-(OH) 2 -Vitamin D 25-OH-Vitamin D C-Peptide Anti-TG

IGF-1

Insulin

Osteocalcin

Procalcitonin

IMMUNOASSAY SPECIALITY 2 PROGRAMME+

 

RQ9142

 

5

parameters

Samples every month, 1 x 12 month cycle, 12 month subscription

 

Calcitonin

Procalcitonin Plasma Renin Activity

 

Renin, direct concentration

Gastrin

 

LIPID PROGRAMME With target scoring

 

RQ9126/a

RQ9126/b

3

Parameters only (choose from 7)

Full 7 Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

 

Apolipoprotein A1

Cholesterol, total

LDL-Cholesterol

Triglycerides

Apolipoprotein B

HDL-Cholesterol

Lipoprotein (a)*

LIQUID CARDIAC PROGRAMME With target scoring

RQ9136

 

10 Parameters Samples every month, 1 x 12 month cycle, 12 month subscription

 
 

BNP

Digoxin

Myoglobin

Troponin T

CK-MB Mass

Homocysteine

NT proBNP

D-Dimer*

hsCRP

Troponin I

MATERNAL SCREENING PROGRAMME With target scoring

RQ9137

 

6

Parameters

Samples every month, 1 x 12 month cycle, 12 month subscription

 

AFP free Beta hCG

total hCG

PAPP-A

Inhibin A

Unconjugated Oestriol

SEROLOGY (EBV) PROGRAMME+

RQ9153

2 parameters

3 samples per quarterly distribution, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Anti-EBV VCA IgG

RED = Parameters with Reference Method Values

Anti-EBNA IgG

PURPLE = The only parameters available on RQ9135/a

Anti-EBV VCA IgM

+ = Programmes awaiting accreditation to ISO/IEC 17043

* = Pilot study ongoing

RIQAS Programmes

SEROLOGY (HIV-HEPATITIS) PROGRAMME+

RQ9151

10 parameters

5 samples per quarterly distribution, 1 x 12 month cycle, 12 month subscription, Qualitative results only

Anti-HIV-1

Anti-HBc

Anti-CMV

Anti-HIV-2

Anti-HTLV-I

HBsAg

Anti-HIV-1&2 Combined

Anti-HTLV-II

Anti-HCV

Anti-HTLV-1&2 Combined

SEROLOGY (SYPHILIS) PROGRAMME+

RQ9154

1 parameter

3 samples per quarterly distribution, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Syphilis (Methods available include immunoassay RPR,VDRL and TPHA)

SEROLOGY (ToRCH) PROGRAMME+

 

RQ9152

12

parameters

5

samples per quarterly distribution, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Anti-Toxoplasma IgG

Anti-CMV IgG

Anti-HSV-1&2 IgG Combined

Anti-Toxoplasma IgM

Anti-CMV IgM

Anti-HSV 1 1gM

Anti-Rubella IgG

Anti-HSV1 IgG

Anti-HSV 2 IgM

Anti-Rubella IgM

Anti-HSV2 IgG

Anti-HSV I + 2 IgM Combined

SPECIFIC PROTEINS PROGRAMME With target scoring

RQ9114 (3ml)

RQ9160 (2ml)

RQ9161 (1ml)

26

parameters,

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

 

AFP

Beta-2-microglobulin

Immunoglobulin A Immunoglobulin E Immunoglobulin G Immunoglobulin M Free Kappa Light Chain Total Kappa Light Chain Free Lambda Light Chain

Total Lambda Light Chain Prealbumin (Transthyretin) Retinol Binding Protein Rheumatoid Factor Transferrin

Albumin

Ceruloplasmin

Alpha-1-acid glycoprotein

Complement, C3

Alpha-1-antitrypsin

Complement, C4

Alpha-2-macroglobulin

C-Reactive Protein

Anti Streptolysin O Antithrombin III

Ferritin

 

Haptoglobin

THERAPEUTIC DRUGS PROGRAMME With target scoring

 

RQ9111

 

18

parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription,Weighed-in values

 

Amikacin

Ethosuximide

Phenobarbital

Tobramycin

Caffeine

Gentamicin

Phenytoin

Valproic acid

Carbamazepine

Lithium

Primidone

Vancomycin

Cyclosporine

Methotrexate

Salicylic acid

Digoxin

Paracetamol (Acetaminophen)

Theophylline

URINALYSIS PROGRAMME+

 

RQ9138

 

14

Parameters

Samples every 2 months, 1 x 12 month cycle, 12 month subscription

 

Albumin

Galactose

Leukocytes

Specific Gravity

 

Bilirubin

Glucose

Nitrite

Urobilinogen

Blood

hCG

pH

Creatinine

Ketones

Protein

URINE TOXICOLOGY PROGRAMME+

RQ9139

 

20

Parameters

Samples every month, 1 x 12 month cycle, 12 month subscription

 

Benzoylecgonine

d-Methamphetamine

MDMA

Phenobarbital

Buprenorphine

EDDP

Methadone

Secobarbitol

Cannabinoids (THC)

Ethanol

Nortriptyline

Cotinine*

Free Morphine

Norpropoxyphene

Creatinine

Lorazepam

Oxazepam

d-Amphetamine

LSD

Phencyclidine

RED = Parameters with Reference Method Values

PURPLE = The only parameters available on RQ9135/a

+ = Programmes awaiting accreditation to ISO/IEC 17043

* = Pilot study ongoing

Participation in RIQAS

Participation in RIQAS Participant registers methods used in their lab by completing enrolment document. Enrolment

Participant registers methods used in their lab by completing enrolment document. Enrolment documents are available from www.riqas.com and should be submitted 3 weeks before the cycle starts. Check RIQAS polices in method questionnaire.

cycle starts. Check RIQAS polices in method questionnaire. Participant recieves a set of numbered samples for

Participant recieves a set of numbered samples for the cycle along with a username/ password to access RIQASNet.

cycle along with a username/ password to access RIQASNet. Participant receives report by e-mail or post.
cycle along with a username/ password to access RIQASNet. Participant receives report by e-mail or post.

Participant receives report by e-mail or post.

RIQASNet. Participant receives report by e-mail or post. Participant reviews the report to assess performance

Participant reviews the report to assess performance

post. Participant reviews the report to assess performance Participant submits the results via RIQASNet, or sends

Participant submits the results via RIQASNet, or sends the return sheet by fax or post, before the “final date” deadline.

    General Clinical

  
General Clinical Chemistry Programme
September 2008 - March 2009
September 2011 - March 2012
Randox Laboratories

 
 

    
            


Participant receives a certificate for participating at the end of the cycle, provided that more than half results are returned.

cycle, provided that more than half results are returned. Participant analyses the sample on the recommended
cycle, provided that more than half results are returned. Participant analyses the sample on the recommended

Participant analyses the sample on the recommended date, carefully following the instructions for use.

date, carefully following the instructions for use. Participant enters the results on RIQASNet or on the
date, carefully following the instructions for use. Participant enters the results on RIQASNet or on the

Participant enters the results on RIQASNet or on the return sheet.

enters the results on RIQASNet or on the return sheet. Method changes and registration of additional

Method changes and registration of additional parameters can be submitted via RIQASNet.

LT033 AUG12

LT033 AUG12 RANDOX INTERNATIONAl HEADquARTERs Randox Laboratories Limited, 55 Diamond Road, Crumlin, County Antrim,

RANDOX INTERNATIONAl HEADquARTERs Randox Laboratories Limited, 55 Diamond Road, Crumlin, County Antrim, United Kingdom, BT29 4QY T +44 (0) 28 9442 2413 F +44 (0) 28 9445 2912 E marketing@randox.com I www.randox.com

Randox has sales and distribution agreements in over 130 countries including Australia, Brazil, China, Czech Republic, France, Germany, Hong Kong, India, Italy, Jamaica, Poland, Portugal, Puerto Rico, Russia, Slovakia, South Africa, South Korea, Spain, Switzerland, USA and Vietnam are directly represented by Randox Companies

USA and Vietnam are directly represented by Randox Companies Australia Randox (Australia) Pty ltd. Suite 2/4

Australia

Randox (Australia) Pty ltd. Suite 2/4 Charles Street, Paramatta, NSW 2150,Australia.

Tel: +61 (0) 2 9615 4640 Fax: +61 (0) 2 9615 4644

Brazil

Randox Brasil ltda Rua Fernandes Moreira, 415 CEP: 04716-000 - São Paulo / SP - Brasil.

Tel: +55 11 5181-2024 Fax: +55 11 5181-0817

China

Randox laboratories ltd. shanghai Representative Office Room 522-523, Fortune Times Tower, No.1438 North, Shanxi Road, Putuo District, Shanghai, China 20060

Tel: +86 021 6288 6240 Fax: +86 021 6288 6246

China 20060 Tel: +86 021 6288 6240 Fax: +86 021 6288 6246 Czech Republic Randox laboratories

Czech Republic

Randox laboratories s.r.o. Bo ř ivojova 35/878 130 00 Praha 3, Czech Republic.

Tel: +420 2 1115 1661 Fax: +420 2 1115 1662

France

laboratoires Randox Roissy Parc, ZAC du Moulin 24-26 rue du Noyer, BP 40, 95700 Roissy en France

Tel: +33 (0) 130 18 96 80 Fax: +33 (0) 130 18 03 60

Germany

Randox laboratories GmbH Wilhelmstr. 147a, 42489 Wülfrath, Germany.

Tel: +49 (0) 2151/93 706-11 Fax: +49 (0) 2151/ 93 706-222

Tel: +49 (0) 2151/93 706-11 Fax: +49 (0) 2151/ 93 706-222 Hong Kong Randox laboratories Hong

Hong Kong

Randox laboratories Hong Kong Room 602, Skyline Commercial Centre, No 71-77 Wing Lok Street, Sheung Wan, Hong Kong

Tel: +852 3595 0515 Fax: +852 3008 5133

India

Randox laboratories India Pvt ltd. 3rd Floor, Godrej Coliseum, Somaiya Hospital Road, Off. Eastern Express Highway, Sion (East), Mumbai - 400 022, India

Tel: +91 22 6714 0600 Fax: +91 22 2408 3803

Italy

Randox laboratories ltd. Corso Montevecchio 37, 10129 Torino, Italy.

Tel: +39 06 9896 8954 Fax: +39 06 6051 3810

Torino, Italy. Tel: +39 06 9896 8954 Fax: +39 06 6051 3810 Poland Randox laboratories ul.Wolnosc

Poland

Randox laboratories ul.Wolnosc 7 lok. 15, 01-018,Warszawa.

Tel: +48 (0) 22 862 1080 Fax: +48 (0) 22 862 1081

Portugal

Irlandox laboratorios quimica Analitica ltda Rua Agostinho de Jesus e Sousa 258, 4000-015 Porto, Portugal.

Tel: +351 22 589 8320 Fax: +351 22 589 8329

Puerto Rico

Randox de Puerto Rico PMB 590 PO Box 29029 San Juan, PR 00929-0029.

Tel: +1 787 701 7000 Fax: +1 787 701 6901

PR 00929-0029. Tel: +1 787 701 7000 Fax: +1 787 701 6901 Republic of Ireland Randox

Republic of Ireland

Randox Teoranta Meenmore, Dungloe, Co Donegal, Republic of Ireland

Tel: +353 7495 22600

slovakia

Randox s.R.O. Vilová 2, 851 01 Bratislava, Slovakia.

Tel: +421 2 6381 3324 Fax: +421 2 6381 2482

south Africa

Randox laboratories (sA) (PTY) ltd Unit 69F Allandale Business Park Cnr. Le Roux Avenue & Morkels Close Halfway House, Midrand, South Africa

Tel: +27 011 461 371

Halfway House, Midrand, South Africa Tel: +27 011 461 371 south Korea Randox Korea ltd. 904

south Korea

Randox Korea ltd. 904 Doosan Venturedime 126-1, Pyeongchon, Dongan-gu,Anyang City, Kyeonggi-do, South Korea

Tel: +82 (0) 31 478 3121 Fax: +82 (0) 31 478 3122

spain

laboratorios Randox s.l. C/Enric Prat de la Riba, 226, 1° Planta, 08901 L’Hospitalet de Llobregat, Barcelona.

Tel: +34 93 475 09 64 Fax: +34 93 475 09 65

switzerland

Randox laboratories ltd. (switzerland) C/O Wirtschafts-Treuhand Auctor Schwyz AG, Oberer Steisteg 18, 6430 Schwyz, Switzerland.

Tel: +41 41 810 48 89 Fax: +41 41 810 48 34

Switzerland. Tel: +41 41 810 48 89 Fax: +41 41 810 48 34 uK Randox laboratories

uK

Randox laboratories ltd. 55 Diamond Road, Crumlin, Co.Antrim, United Kingdom, BT29 4QY

Tel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912

usA

Randox laboratories-us, ltd. 515 Industrial Boulevard, Kearneysville,West Virginia, 25430

Tel: +1 304 728 2890 Toll Free: 8664 RANDOX Fax: +1 304 728 1890 Toll Free: 8664 RANDOX 1

Vietnam

Randox laboratories ltd.Vietnam Villa Phuc Thinh 2Bis Nguyen Thi Minh Khai St. Dakao Ward, District 1, Ho Chi Minh City,Vietnam.

Tel: +84-8-39 11 09 04 Fax: +84-8-39 11 09 05
Tel: +84-8-39 11 09 04
Fax: +84-8-39 11 09 05

RIQAS

T +44 (0) 28 9442 2413 E mail@riqas.com I RIQAS NET www.riqas.net I www.riqas.com

Information correct at time of print. Randox Laboratories Limited is a company registered within Northern Ireland with company number NI 15738. VAT Registered Number: GB 353 030 400. Product availability may vary from country to country. Please contact your local Randox representative for information.